Menu
MorphoSys US

It’s our mission to deliver innovative therapies to improve the lives of patients impacted by cancer and autoimmune diseases.

Learn more about MorphoSys’ agreement to acquire Constellation Pharmaceuticals and our strategic funding partnership with Royalty Pharma

CLICK HERE >

Latest
news

04/06/2021
MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study...
Read Media Release
02/06/2021
MorphoSys to Acquire Constellation Pharmaceuticals
Read Media Release
02/06/2021
MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into...
Read Media Release
21/05/2021
MorphoSys To Participate in UBS Global Healthcare Conference
Read Media Release
19/05/2021
MorphoSys to Present Data on Tafasitamab (Monjuvi(R)) at the 2021 ASCO...
Read Media Release
11/05/2021
MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND...
Read Media Release
05/05/2021
MorphoSys AG Reports First Quarter 2021 Results
Read Media Release
28/04/2021
Invitation to MorphoSys' First Quarter Results Conference Call on May...
Read Media Release
19/04/2021
MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study...
Read Media Release
15/03/2021
MorphoSys AG Presents Results for Full Year 2020
Read Media Release

June 8, 2021
Fireside Chat
Goldman Sachs 42nd Annual Global Healthcare Conference

Full details

You are leaving morphosys.com and will be transferred to the MorphoSys US website which is intended for US residents.

Do you wish to proceed?

Yes No

You are leaving morphosys.com and will be transferred to the MorphoSys US website which is intended for US residents.

Do you wish to proceed?

Yes No

You are leaving morphosys.com and will be transferred to the Monjuvi(®) US website which is intended for US residents.

Do you wish to proceed?

Yes No